Advanced Search

 

Study ID Status Title Patient Level Data
21 Completed Six week, parallel, double blind, randomized comparison of bupropion versus amitriptyline (75-225mg/day) in inpatients - Extensive searching has revealed that no clinical study report is available for this study. The clinical trial results were reported via publication; see citations below.
210602-002 Completed Assess the feasibility of an investigational vaccination regimen, compared to a 3-dose primary vaccination with GSK Biologicals' Infanrix hexa™ (DTPa-HBV-IPV/Hib vaccine) following hepatitis B vaccination at birth. Primary vaccination is followed in the 2nd year of life by a booster dose of Infanrix-hexa Study Listed on ClinicalStudyDataRequest.com
213501/016 Completed A post-marketing surveillance study of GlaxoSmithKline (GSK) Biologicals Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B vaccine (TRITANRIX-HB) and Haemophilus influenzae type-b tetanus-conjugate (Hib) vaccine (HIBERIX)co-administered in the same syringe in 1,000 Filipino subjects. Study Listed on ClinicalStudyDataRequest.com
213501/018 Completed Study to evaluate immunogenicity, safety and reactogenicity of two different immunization regimens against hepatitis B, diphtheria, tetanus, pertussis and Haemophilus influenzae type b (Hib)diseases in healthy infants primed with a birth dose of GSK Biologicals hepatitis B Study Listed on ClinicalStudyDataRequest.com
213501/019 Completed Study to assess immunogenicity and reactogenicity of GSK Biologicals’ quadrivalent diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B and Haemophilus influenzae type b conjugate vaccines when mixed extemporaneously and given in a single injection to healthy infants Study Listed on ClinicalStudyDataRequest.com
213501/021 Completed Study to assess immunogenicity and reactogenicity of GSK Bio’s combined diphtheria-tetanus-whole cell Bordetella pertussis-hepatitis B/Haemophilus influenzae type b vaccine injected in healthy infants previously primed at birth with hepatitis B vaccination.
213503/004 Completed Immunogenicity and reactogenicity study of GSK’s combined diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, coadministered with GSK’s Haemophilus influenzae type b conjugate vaccine, either in 2 concomitant injections or mixed in one injection, given to healthy infants at 2, 4 and 6 months
213503/005 Completed Consistency study in terms of immunogenicity & reactogenicity of 2 lots of GSK’s DTPa-IPV vaccine coadministered with GSK’s Hib vaccine, either simultaneously in 2 separate injections or mixed in 1 single injection, as a primary vaccination course to healthy infants at 2, 4 and 6 months
213503/013 Completed Immunogenicity & reactogenicity study of coadministration of GSK’s DTPa-IPV vaccine & GSK’s Hib vaccine, either mixed & given in 1 single injection, or given in 2 concomitant injections, as a booster vaccination to healthy children, previously primed with a 3 dose primary vaccination course using same vaccine
213503/026 Completed Reactogenicity and immunogenicity study of GSK’s DTPa coadministered with GSK’s Hib in 2 concomitant injections or mixed and to GSK’s DTPa-IPV mixed with GSK’s Hib, administered as a booster to healthy children in their second year of life, previously primed with 3 doses of GSK’s DTPa-HBV-IPV
213503/044 Completed Open study to assess the immunogenicity after two and three doses of GSK Biologicals’ Hib vaccine combined with GSK Biologicals’ DTPa-IPV vaccine given to Swedish infants in a 3, 5, 12 month schedule Study Listed on ClinicalStudyDataRequest.com
213503/045 Completed Study to compare immunogenicity and reactogenicity of GSK Bio’s DTPa-IPV vaccine, with GSK Bio’s DTPa (Infanrix) and Aventis MSDs IPV vaccine (Imovax Polio) administered separately to healthy children 4 to 6 years of age Study Listed on ClinicalStudyDataRequest.com
213503/046 Completed Open, randomised phase IIIb, clinical trial to compare the immunogenicity and reactogenicity of GSK Biologicals’ DTaP-IPV vaccine, with GSK Biologicals’ DTaP and Aventis Pasteur MSD’s IPV vaccines administered to healthy children, previously vaccinated with 4 doses of DTaP and polio vaccines, and co-administered with GSK Biologicals’ MMR vaccine Study Listed on ClinicalStudyDataRequest.com
213503/047 Completed Open, randomized, phase II, clinical trial to compare the immunogenicity and safety of a booster dose of GSK Biologicals' DTaP-IPV vaccine (Infanrix®-IPV) co-administered with a booster dose of Merck and Company's M-M-R®II, to that of separate injections of GSK Biologicals' DTaP vaccine (Infanrix®), Aventis Pasteur's IPV (IPOL®) and M-M-R®II administered as booster doses to healthy children 4 to 6 years of age. Study Listed on ClinicalStudyDataRequest.com
213503/048 Completed Safety, immunogenicity&consistency of 3 manufacturing lots of DTaP-IPV vaccine vs separate injections of GSK Biologicals' DTaP + Aventis Pasteur's IPV admd as booster doses to healthy children 4-6 yrs, each co-admd with Merck's MMR vaccine Study Listed on ClinicalStudyDataRequest.com
213503/049 Completed An open, multicentre, phase IV booster vaccination study to assess the immunogenicity and reactogenicity of GSKBiologicals combined Infanrix-IPV+Hib (DTPa-IPV/Hib) vaccine in healthy children aged 17 to 20 months whocompleted a three-dose primary vaccination course Study Listed on ClinicalStudyDataRequest.com
213503/050 Completed Study to evaluate safety and immunogenicity of a booster dose of DTPa-IPV/Hib at 18 months of age with GSK Biologicals DTPa-IPV/Hib compared to Aventis Pasteurs Pentacel, after an initial primary vaccination series administered at 2, 4, and6 months of age with Aventis Pasteurs Pentacel Study Listed on ClinicalStudyDataRequest.com
217744/001 Completed Open randomised clinical study to evaluate the immunogenicity and reactogenicity of SmithKline Beecham Biologicals’ combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine in comparison to SmithKline Beecham Biologicals' combined diphtheria, tetanus, acellular pertussis, hepatitis B vaccine when co-administered with inactivated poliovirus vaccine as two separate injections in opposite limbs and administered as primary vaccinations to healthy infants at 3, 4 and 5 months of age
217744/002 Completed Open clinical study to evaluate the immunogenicity and reactogenicity of SmithKline Beecham Biologicals' combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine. The vaccines will be administered as primary vaccinations to healthy infants at 2, 4, and 6 months of age
217744/004 Completed Open clinical study to evaluate the immunogenicity and reactogenicity of SmithKline Beecham Biologicals’ combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine, co-administered with commercially available Haemophilus influenza type b vaccine as two separate injections in opposite limbs. The vaccines will be administered as primary vaccination to healthy infants at 2, 4 and 6 months of age
217744/010 Completed Open clinical study to evaluate the immunogenicity and reactogenicity of SB Biologicals' DTPa-HBV-IPV vaccine, co-administered with SB Biologicals' Hib vaccine as two separate injections in opposite limbs
217744/011 Completed Randomised clinical study to assess the safety and reactogenicity of SB Biologicals' DTPa-HBV-IPV vaccine, when co-administered with Hib vaccine in two concomitant injections into opposite limbs, as a primary vaccination course to healthy infants at the age of 3, 4 and 5 months
217744/012 Completed Randomised clinical study to assess the immunogenicity and reactogenicity of SB Biologicals' DTPa-HBV-IPV vaccine, when co-administered with Hib vaccine in two concomitant injections into opposite limbs, as a primary vaccination course to healthy infants at the age of 3, 4½ and 6 months
217744/015 Completed An open study of the safety and immunogenicity of DTPa-HBV-IPV vaccine administered as a three dose series or in a sequential IPV/OPV schedule at 2, 4, and 6 months of age
217744/028 Completed Study to assess the safety and reactogenicity of SB Biologicals DTPa vaccine, co-administered with commercial Hib vaccine as compared to SB Biologicals' DTPa vaccine-SB Biologicals' DTPa-IPV vaccine each time mixed with SB Biologicals’ Hib vaccine, and to SB Biologicals’ DTPa-HBV-IPV vaccine co-administered with SB Biologicals’ Hib vaccine

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.